Ann: ATL1102 DMD Paediatric Investigation Plan submitted to EMA, page-47

I think they're talking calender year.

In the Paediatric Investigation Plan for ATL1102 in DMD submitted to European MedicinesAgency they say "The Company has commenced the manufacture of ATL1102 active ingredient for the Phase IIb trial andis planning to have this material formulated into injectable product in Q2’21."
It hasn't finished yet so Q2'21 is Q2 2021.

Also in that document, "Approvals will likely then be staggered depending upon the approval timelines of the individual states. Allgoing well first approvals would be anticipated in Q3’21 with site initiation in Q4’21". If site initiation is in Q4 2021 dosing won't start until 2022.